interleukin-2/interleukin-15 receptor agonist NL-201
Term · Oncology and biomedicine · MLC-T-ONC-014483
An interleukin-2 (IL-2) and interleukin-15 (IL-15) receptor agonist with high binding affinity for the common heterodimeric receptor IL-2Rbeta-gamma, which is composed of the IL-2 receptor subunit beta (IL-2Rbeta; CD122) and IL-2 receptor subunit gamma (IL-2Rgamma; common gamma; CD132), and no binding affinity for the IL-2 receptor subunit alpha (IL-2Ralpha; CD25), with potential immunoregulatory and antineoplastic activities. Upon administration, IL-2/IL-15 receptor agonist NL-201 targets and binds to IL-2Rbeta-gamma on natural killer (NK) and T cells and activates IL-2Rbeta-gamma-mediated signaling. This induces the selective proliferation of CD8+ T cells and NK cells, enhances tumor cell killing and decreases tumor cell proliferation. NL-201 does not bind to IL-2Ralpha, thereby circumventing both the activation of immunosuppressive regulatory T cells (Tregs) and the exacerbation of vascular leak syndrome associated with recombinant human IL-2. IL-2 and IL-15 receptors are cytokine receptors that play key roles in the immune response.
| Identifier | MLC-T-ONC-014483 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | IL-2/IL-15 receptor agonist NL-201 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014483",
"term": "interleukin-2/interleukin-15 receptor agonist NL-201",
"field": "Oncology and biomedicine",
"definition": "An interleukin-2 (IL-2) and interleukin-15 (IL-15) receptor agonist with high binding affinity for the common heterodimeric receptor IL-2Rbeta-gamma, which is composed of the IL-2 receptor subunit beta (IL-2Rbeta; CD122) and IL-2 receptor subunit gamma (IL-2Rgamma; common gamma; CD132), and no binding affinity for the IL-2 receptor subunit alpha (IL-2Ralpha; CD25), with potential immunoregulatory and antineoplastic activities. Upon administration, IL-2/IL-15 receptor agonist NL-201 targets and binds to IL-2Rbeta-gamma on natural killer (NK) and T cells and activates IL-2Rbeta-gamma-mediated signaling. This induces the selective proliferation of CD8+ T cells and NK cells, enhances tumor cell killing and decreases tumor cell proliferation. NL-201 does not bind to IL-2Ralpha, thereby circumventing both the activation of immunosuppressive regulatory T cells (Tregs) and the exacerbation of vascular leak syndrome associated with recombinant human IL-2. IL-2 and IL-15 receptors are cytokine receptors that play key roles in the immune response.",
"synonyms": [
"IL-2/IL-15 receptor agonist NL-201"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/interleukin-2-interleukin-15-receptor-agonist-nl-201/"
}
Record 9,346 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.